Top Stock Picks for the Day: Juno Therapeutics, Inc. (JUNO), Depomed, Inc. (DEPO)

Juno Therapeutics, Inc. (NASDAQ:JUNO) shares were trading higher by 0.74 percent ($0.32) at $43.4 a piece in Thursday’s session. It had closed the previous session at $43.08. JUNO trades with a P/S ratio of 58.92. This is lower than the industry’s 133.61 but higher compared with the wider sector’s 13.99. A low price-to-sales ratio, typically less than 1.0, is considered a good value. . Shares of JUNO have uptrended 46.18% in the past three months, while the S&P 500 has moved 42.52% in that time. Juno Therapeutics, Inc. (JUNO) has a market cap of $4.87 billion and over the last 12 months, Juno Therapeutics, Inc. (NASDAQ:JUNO) has gone stronger by 63.4%. During the last 52 weeks, the (NASDAQ:JUNO) price has been as high as $47.03 and as low as $17.52. Juno Therapeutics, Inc. earnings have declined with an annualized rate of 0% over the last 5 years.

Juno Therapeutics, Inc. (Mean Target Price: $42)

The average 1-year price target for Juno Therapeutics, Inc. (JUNO) — averaging the work of different analysts — reveals a mean PT of $42/share. That’s a potential -3.23 decrease relative to where Juno Therapeutics, Inc. (NASDAQ:JUNO) has been trading recently. The current price is seen ranging between $42.35 and $44.5. There are brokerage firms with lower targets than the average, including one setting a price target of $25. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $56.

Juno Therapeutics, Inc. (JUNO) Consensus Recommendation

The collective rating of 2 for Juno Therapeutics, Inc. (NASDAQ:JUNO) also leans strongly towards the neutral end of the spectrum. Of the 14 analysts surveyed by Reuters that track JUNO 5 of them rate its stock a hold. The other 9, though not evenly; between analysts who think you should buy Juno Therapeutics, Inc. versus those who think you should sell it. A 9 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of JUNO or, if they already own its stock, sell it.

Is Depomed, Inc. (NASDAQ:DEPO) Cheap From Peers?

Depomed, Inc. (DEPO) pulled off a 0.74 percent gain and now trades for $5.43. DEPO comes in with a P/S ratio of 0.8 that’s below 1, potentially implying that it could be cheap relative to the overall sector (13.99) and its peers (133.61). Also, it has an estimated price-earnings (P/E) multiple of 7.99 . During the last 52 weeks, the price has been as high as $24.09 and as low as $4.93. Depomed, Inc. (NASDAQ:DEPO) earnings have risen with a quarterly rate of 27.9% over the last 5 years. Shares of DEPO have sank -48.77% in the past three monthswhile the S&P 500 has dropped -48.67% in that time.

Depomed, Inc. (Price Objective: $8.14)

Depomed, Inc. (NASDAQ:DEPO) has a market cap of $340.03 million and over the last 12 months, DEPO has declined by -76.94%. The average 1-year price target for (DEPO) reveals an average price target of $8.14 per share. That’s a potential 49.91 gain from where (NASDAQ:DEPO) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $5. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $12.

Analyst Thoughts About Depomed, Inc. (NASDAQ:DEPO)

The consensus recommendation — averaging the work of 7 analysts — of 3 for Depomed, Inc. (DEPO) points to moderate case. Of the analysts surveyed by Reuters that track Depomed, Inc. 5 of them rate its stock a hold. The other 2 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 1 analysts rate it as either a buy or a strong buy, while 1 believe that investors should either steer clear of (NASDAQ:DEPO) or, if they already own its stock, sell it.